| Literature DB >> 21708021 |
Ryan M Stepan1, Julie S Sherwood, Shana R Petermann, Catherine M Logue.
Abstract
BACKGROUND: Salmonella species are recognized worldwide as a significant cause of human and animal disease. In this study the molecular profiles and characteristics of Salmonella enterica Senftenberg isolated from human cases of illness and those recovered from healthy or diagnostic cases in animals were assessed. Included in the study was a comparison with our own sequenced strain of S. Senfteberg recovered from production turkeys in North Dakota. Isolates examined in this study were subjected to antimicrobial susceptibility profiling using the National Antimicrobial Resistance Monitoring System (NARMS) panel which tested susceptibility to 15 different antimicrobial agents. The molecular profiles of all isolates were determined using Pulsed Field Gel Electrophoresis (PFGE) and the sequence types of the strains were obtained using Multi-Locus Sequence Type (MLST) analysis based on amplification and sequence interrogation of seven housekeeping genes (aroC, dnaN, hemD, hisD, purE, sucA, and thrA). PFGE data was input into BioNumerics analysis software to generate a dendrogram of relatedness among the strains.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21708021 PMCID: PMC3224216 DOI: 10.1186/1471-2180-11-153
Source DB: PubMed Journal: BMC Microbiol ISSN: 1471-2180 Impact factor: 3.605
MLST Primers and PCR Primers used in the amplification of the genes and the expected product sizes used in this study.
|
|
|
|
|---|---|---|
| 852 bp | ||
| 510 bp | ||
| 643 bp | ||
| 894 bp | ||
| 826 bp | ||
| 666 bp | ||
| 833 bp | ||
Figure 1Dendrogram displaying PFGE profiles, antimicrobial resistance profiles and sequence types (ST) of . Key for antimicrobial abbreviations - see table 2.
Antimicrobial resistance among animal, human and miscellaneous sources of S. Senftenberg
| Antimicrobial | Breakpoint | Animal | Human | Other |
|---|---|---|---|---|
| Amikacin (AMI) | ≥64 | 0 | 0 | 0 |
| Amoxicillin/Clavulanic Acid (AUG) | ≥32/16 | 7 (9.8%) | 0 | 0 |
| Ampicillin (AMP) | ≥32 | 14 (19.7%) | 0 | 0 |
| Cefoxitin (FOX) | ≥32 | 8 (11.2%) | 0 | 0 |
| Ceftiofur (TIO) | ≥8 | 8 (11.2%) | 0 | 0 |
| Ceftriaxone (AXO) | ≥4 | 8 (11.2%) | 0 | 0 |
| Chloramphenicol (CHL) | ≥32 | 11 (15.4%) | 0 | 0 |
| Ciprofloxacin (CIP) | ≥4 | 0 | 0 | 0 |
| Gentamicin (GEN) | ≥16 | 13 (18.3%) | 0 | 1 (20%) |
| Kanamycin (KAN) | ≥64 | 26 (36.6%) | 0 | 1 (20%) |
| Nalidixic Acid (NAL) | ≥32 | 0 | 0 | 0 |
| Streptomycin (STR) | ≥64 | 21 (29.5%) | 0 | 1 (20%) |
| Sulfisoxazole (FIS) | ≥256 | 37 (52.1%) | 0 | 1 (20%) |
| Tetracycline (TET) | ≥16 | 34 (47.8%) | 0 | 1 (20%) |
| Trimethroprim/Sulfamethoxazole (SXT) | ≥4/76 | 11 (15.4%) | 0 | 0 |
Resistance patterns among 51 S. Senftenberg recovered from animal and miscellaneous sources
| Pattern | # of isolates with pattern |
|---|---|
| CHL | 1 |
| FIS | 2 |
| KAN | 1 |
| SXT | 5 |
| TET | 1 |
| FIS, TET | 3 |
| GEN, FIS | 1 |
| STR, SXT | 3 |
| STR, TET | 1 |
| STR, TET, SXT | 4 |
| TIO, TET | 1 |
| TIO, FIS, TET | 1 |
| KAN, FIS | 1 |
| KAN, STR, FIS | 1 |
| KAN, FIS, SXT | 1 |
| KAN, FIS, TET | 3 |
| KAN, STR, TET, SXT | 1 |
| KAN, FIS, TET, SXT | 3 |
| GEN, KAN, STR, FIS | 1 |
| GEN, KAN, STR, FIS, TET | 1 |
| GEN, KAN, STR, FIS, TET, SXT | 1 |
| AMP, KAN, STR, TET | 1 |
| AMP, KAN, STR, FIS, TET | 1 |
| AMP, GEN, KAN, FIS, TET | 1 |
| AMP, GEN, KAN, STR, FIS, TET | 1 |
| AMP, CHL, GEN, KAN, STR, FIS, TET | 1 |
| AMP, GEN, KAN, STR, FIS, TET, SXT | 1 |
| AUG, GEN, KAN, STR, TET, SXT | 1 |
| AUG, AMP, FOX, TIO, STR, FIS, TET, SXT | 1 |
| AUG, AMP, FOX, TIO, CHL, STR, FIS, TET | 2 |
| AUG, AMP, FOX, TIO, KAN, STR, FIS, TET, SXT | 1 |
| AUG, AMP, FOX, TIO, CHL, KAN, STR, FIS, TET, SXT | 1 |
| AUG, AMP, FOX, TIO, CHL, GEN, KAN, STR, FIS, TET, SXT | 2 |
CHL - chloramphenicol, FIS - sulfisoxazole, KAN - kanamycin, SXT - trimethoprim/sulfamethoxazole, TET - tetracycline, GEN - gentamicin, STR - streptomycin, TIO - ceftiofur, AMP - ampicillin, AUG - amoxicillin/clavulanic acid, FOX - cefoxitin.